Postmenopausal Osteoporosis Market Growth, Size, Share, Industry Report and Forecast 2021-2027

The global postmenopausal osteoporosis market is anticipated to grow at a CAGR of around 3.6% during the forecast period (2021-2027). The key factor that drives the market includes the increasing prevalence of osteoporosis disease among the aged population. For instance, according to International Osteoporosis Foundation, United Nations estimates that the "old age" dependency ratio will be increasing dramatically in the 21st century. By 2030, the ratio is forecasted to be 18 seniors per 100 workers which will be further increased to 25.2 per 100 and 37.6 per 100 by 2050. Almost 9 million fragility fractures are taking place annually that includes 1.6 million hip fractures resulting in premature deaths.

To Request a Sample of our Report on Postmenopausal Osteoporosis Market: https://www.omrglobal.com/request-sample/postmenopausal-osteoporosis-market

Rising acquisitions, product approval, product launch collaborations among the major players of the market also propels the growth of the market.
For instance, in April 2019, Amgen and UCB announced that the US food and Drug Administration has approved EVENITY for the treatment for postmenopausal osteoporosis in women with a high risk of fractures. EVENITY is one of the first and only bone builder products that have the unique dual effect of increasing bone formation and reducing bone resorption that rapidly reduces the risk of fracture. This approval comes with the post-marketing requirement of the FDA that gives assess of cardiovascular safety of EVENITY in osteoporosis in women with post-menopause.

(Get 15% Discount on Buying this Report)
A full Report of Postmenopausal Osteoporosis Market is Available at: https://www.omrglobal.com/industry-reports/postmenopausal-osteoporosis-market

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
Segment Covered-
• By Treatment
• By Distribution channel

Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape- Eli Lilly and Co, Pfizer Inc., Proctor & Gamble Co., Amgen Inc., Novartis International AG, Allergan plc.
Global Postmenopausal Osteoporosis Market Report Segment
By Treatment

• Bisphosphonates
• Hormones
• Strontium Ranelate
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E- Commerce Pharmacies

Regional Analysis

North America
• United States
• Canada
Europe
• UK
• Germany
• Spain
• France
• Italy
• Rest of Europe
Asia-Pacific
• India
• China
• Japan
• Rest oF APAC
Rest of The World
• Latin America
• Middle East & Africa
Company Profiles
• Allergan Plc
• Amgen Inc.
• Biologicsmd, Inc.
• Eli Lilly And Co.
• F. Hoffmann-La Roche Ltd.
• Glaxosmithkline Plc
• Ligand Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Novartis International AG
• Novo Nordisk Inc.
• Outlook Therapeutics, Inc.
• Paras Biopharmaceuticals Finland Oy
• Pfizer Inc.
• Phytohealth Corp.
• Procter & Gamble Co.
• Radius Health Inc.
• Sanofi S.A.
• Tarsa Therapeutics, Inc.
• Teva Pharmaceuticals Industries Ltd.

Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/postmenopausal-osteoporosis-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.